Corona Remedies IPO: An Analyzed Forecast

Corona Remedies, a pharmaceutical company, is planning to start trading on the stock market on December 15, 2025. Early signs show the IPO is expected to be very successful. The company raised ₹655.7 crore by selling shares to the public.

Key Points

• Strong investor interest: IPO oversubscribed 137 times.
• QIBs dominated: Quota booked 278.52 times.
• NIIs and Retail investors showed good demand.
• Grey market price indicates a 29% potential gain.
• Grey market data is unofficial; use cautiously.
• IPO details: ₹655.7 crore raised, 14 share lots.

The IPO involved selling 6.2 million shares. The price was set between ₹1,008 and ₹1,062 per share. This means investors can buy at least 14 shares.

Investors were very interested in buying shares, with the entire offering oversubscribed by 137 times. Qualified Institutional Buyers (QIBs) were especially keen, booking their full allocation 278.52 times. Non-institutional investors and retail investors also showed significant demand, oversubscribing their portions by 208.88 times and 28.73 times, respectively.

As of December 11, 2025, the company decided how to distribute the shares. Now, investors are waiting for the stock to start trading on Dalal Street.

Before the launch, the company’s shares were trading well in the grey market. These shares were worth around ₹1,372 each – that’s 29.2% higher than the original price of ₹1,062, according to information from unofficial markets.

If the grey market’s performance continues, the Corona Remedies stock is likely to start trading around ₹1,372. This could give investors a 29% profit when they buy the shares.

However, experts warn that the grey market doesn’t follow the same rules as the stock market. So, the grey market’s price isn’t a guaranteed prediction of the stock’s value.

The IPO’s proceeds won’t go to the company. Instead, the original owners of the company will sell their shares. The main shareholders selling their shares are Kirtikumar Laxmidas Mehta, Minaxi Kirtikumar Mehta, Dipabahen Niravkumar Mehta, and Brinda Ankur Mehta. Other investors selling shares include Sepia Investments, Anchor Partners, and Sage Investment Trust.

Successful IPOs are a gauge of investor confidence and future growth potential.